Betta Pharmaceutical announced at noon on November 26 that the company received the “Notice of Acceptance” issued by the State Drug Administration. The marketing license application for ensartinib hydrochloride capsules declared by the company is intended to be used for “post-operative adjuvant treatment for patients with stage IB to stage IIIB non-small cell lung cancer with positive anaplastic lymphoma kinase. Patients must have previously undergone surgical resection treatment, and the doctor decides whether to accept or not receive adjuvant chemotherapy” has been accepted by the NMPA.

Zhitongcaijing · 11/26/2025 03:57
Betta Pharmaceutical announced at noon on November 26 that the company received the “Notice of Acceptance” issued by the State Drug Administration. The marketing license application for ensartinib hydrochloride capsules declared by the company is intended to be used for “post-operative adjuvant treatment for patients with stage IB to stage IIIB non-small cell lung cancer with positive anaplastic lymphoma kinase. Patients must have previously undergone surgical resection treatment, and the doctor decides whether to accept or not receive adjuvant chemotherapy” has been accepted by the NMPA.